Cosette Wheeler, Ph.D.

photo of Cosette Wheeler

Regent’s Professor, Pathology and Obstetrics and Gynecology

Email: CWheeler@salud.unm.edu
Lab Website: IHPC - Interdisciplinary HPV Prevention Center


Education and Certification Information

B.S., Chemistry (ACS)/Microbiology (Dual Major)
Northern Arizona University
Flagstaff, AZ
1980

Ph.D., Molecular Biology/Virology (Major)
Cell and Developmental Biology (Minor)
University of Arizona
Tucson, AZ
1985

Resident Research Associate
National Research Council
Infectious Disease Epidemiology Fellowship
Division of Viral Diseases
Centers for Disease Control
Atlanta, GA
1986-87


Selected Publications:

  • Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA, Castle PE. A Population-based Study of HPV Genotype Prevalence in the United States: Baseline Measures Prior to Mass HPV Vaccination. In Press 2012 Int J Cancer.

  • Lehtinen M, Paavonen J, Wheeler CM, Jaisamaran U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; for the HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2011 Nov 8. [Epub ahead of print]

  • Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; for the HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2011 Nov 8. [Epub ahead of print]

  • FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuoccolo S, Hesley TM, Barr E, Haupt R. Four year efficacy of prophylactic human paopillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts; randomized controlled trial. BMJ. 2010 Jul 20;341:c3493.

  • Munoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Avila-Hernandez M, Wheeler CM, Perez G, Brown, DR, Koutsky LA, Tay EH, Garcia P, Ault K, Garland SM, Leodolter S, Olsson S-E, Tang WK, Ferris DG, Paavonnen, J, Steben M, Bosch X, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers E, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Gicoletti KED, James M, Vuocolo S, Hesley TM, Barr E, Haupt R. Population impact of a quadrivalent HPV 6/11/16/18 vaccine on all HPV genital disease in women 16 – 26 years of age. J Natl Cancer Inst 2010 Feb 5. [Epub ahead of print]

  • Castle PE, Schiffman M, Wheeler CM, Wentzensen N and Gravitt PE. The Impact of Improved Classification on the Association of Human Papillomavirus with Cervical Precancer. American Journal of Epidemiology 2010 Jan 15;171(2):155-63. Epub 2009 Dec 10.

  • Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, Castle PE. HPV Genotypes Among U.S. Hispanic and Non-Hispanic White Women: Implications for Vaccination and Cervical Cancer Screening. J Natl Cancer Inst. 2009 Apr 1;101(7):475-87. Epub 2009 Mar 24.See Editorial Commentary, JNCI news and PodCast in same Journal Issue

  • Wilkinson DE, Baylis SA, Padley D, Heath AB, Ferguson M, Pagliusi SR, Quint WG, Wheeler CM; on behalf of the Collaborative Study GroupStudy Participants: Dr. Robert D. Burk, Albert Einstein College of Medicine, Bronx, NY, USA; Dr. Francesca Maria Carozzi, Cancer Prevention and Research Institute (ISPO), Analytical Cytology and Molecular Unit, Florence Italy; Dr. Bhudev Das, Institute of Cytology and Preventive Oncology (ICMR), Division of Molecular Oncology, Noida, India; Dr. Joakim Dillner and Dr. Ola Forslund, Department of Medical Microbiology, University Hospital, Malmö Sweden; Professor Suzanne M. Garland, Miss Anna Maria Costa, Dr. Matthew Stevens, and Associate Professor Sepehr Tabrizi, Royal Women's Hospital, Department of Obstetrics and Gynecology, University of Melbourne, Carlton Victoria, Australia; Dr. Patti E. Gravitt, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Dr. Renee M. Howell, Qiagen Inc., Gaithersburg, MD, USA; Dr. Janet R. Kornegay, Mr. Mark Sadorra, Mr. Thanh Tam, Roche Molecular Systems, Inc., Pleasanton, CA, USA; Dr. Belen Lloveras, Institut Català d'Oncologia Citodiagnostic, Hospital Duran i Reynals, Laboratori de Recerca Translacional‐ Planta 3, Barcelona Spain; Hospital del Mar‐IMAS Barcelona Spain; Dr. Jong‐Sup Park, Dr. Jeong‐Hoon Bae, Dr. Sung‐Jong Lee and Dr. Eun‐Mi Ho, Catholic Research Institute of Medical Science, Seoul St. Mary's Hospital, Department of Obstetrics and Gynecology, Seoul South Korea; Dr. Wim Quint, DDL Diagnostic Laboratory, Voorburg, The Netherlands; Dr. Roland Sahli, Molecular Biology Platform Institute of Microbiology, Lausanne Switzerland; Ms. Sukhon Sukvirach, Field Study Research Section, National Cancer Institute, Bangkok Thailand; Dr. Alexandra Sargent, Department of Clinical Virology, Manchester Royal Infirmary, Manchester UK; Dr. Elizabeth Unger and Dr. David C. Swan, Centers for Disease Control and Prevention, Atlanta, GA, USA; Dr. Luisa Lina Villa, Dr. Andrea Trevisan, Ms. Maria Cecilia Costa, Ms. Maria Antonieta Andreoli, Mr. José Carlos Mann Prado, Mr. João Simão Sobrinho, Ludwig Institute for Cancer Research, Hospital Alemão Oswaldo Cruz, São Paulo, SP Brazil; Dr. Cosette Wheeler, Ms. Cheri Peyton-Goodall, Ms. Norah Torrez‐Martinez, Mr. George Montoya, Ms. Erika Ingersoll, Ms. Amanda Pearse, University of New Mexico Health Sciences Center, Department of Pathology, Albuquerque, NM, USA; Dr. Dianna E. Wilkinson, Division of Virology, National Institute for Biological Standards and Control, South Mimms, Hertfordshire UK; Professor Anna‐Lise Williamson and Mr. Bruce R. Allan, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA.Int J Cancer. 2009 Nov 10. [Epub ahead of print]

  • Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchner HC, Castellsague X, Teixeira J, Skinner R, Hedrick JA, Jaisamram U, Limson GA, Garland SM, Szarewski A, Romanowski B, Poppe L, Aoki F, Schwarz T, Bosch XF, Jenkins D, Lehtinen M, Dubin G for the PATRICIA TRIAL Investigators. Efficacy of a prophylactic AS04 adjuvanted vaccine against infection with human papillomavirus types 16 and 18 in young women: final analysis of a phase III, double-blind, randomised, controlled trial. Lancet. 2009 Jul 25;374(9686):301-14. Epub 2009 Jul 6.

  • Wheeler CM, Kjaer SK, Sigurdsson K, Iversen O-E, Avila-Hernandez M, Perez G, Brown, DR, Koutsky LA, Tay EH, Garcia P, Ault K, Garland SM, Leodolter S, Olsson S-E, Tang WK, Gerris DG, Paavonnen, J, Steben M, Bosch X, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers E, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Gicoletti KED, James M, Vuocolo S, Hesley TM, Barr E. The Impact Of Quadrivalent HPV (Types 6/11/16/18) L1 VLP Vaccine On Infection And Disease Due To Oncogenic Non-Vaccine HPV Types In Sexually Active Women Aged 16-26. J Infect Dis. 2009 Apr 1;199(7):936-44. See Editorial Commentary in Same Journal Issue

  • Garland SM, Hernandez-Avila M, Wheeler CM, Perez, G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky L for the FUTURE I Study Investigators. Efficacy and safety of a quadrivalent prophylactic human papillomavirus (types 6/11/16/18) l1 virus-like-particle vaccine against cervical, vulvar, and vaginal disease and anogenital warts: a randomized controlled trial. New England Journal of Medicine. 2007:356(19):14-29. See Editorial Commentary in same Issue

Search PubMed:

Cosette Wheeler on PubMed